X0206 3 2021-06-16 0 0001806952 Lyell Immunopharma, Inc. LYEL 0001591178 Klausner Richard C/O LYELL IMMUNOPHARMA, INC. 400 EAST JAMIE COURT, SUITE 301 SOUTH SAN FRANCISCO CA 94080 1 1 0 0 Executive Chairman Common Stock 2967834 D Option (right to buy) 0.10 2028-11-05 Common Stock 2713756 D Option (right to buy) 3.65 2030-01-15 Common Stock 650000 D Option (right to buy) 3.65 2029-08-30 Common Stock 4675392 D Series A Convertible Preferred Stock 1.8288 Common Stock 3765842 I Lyell Investors, LLC 1/4 of the shares vested on August 1, 2019, with the remaining shares to vest in equal monthly installments (145,833) over the following thirty-six months. 1/4 of the option shares vested on September 20, 2019, with the remaining option shares to vest in equal monthly installments over the following thirty-six months. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. The shares vest in equal monthly installments over the forty-eight months following February 1, 2020. The shares vest in equal monthly installments over the forty-eight months following July 9, 2019. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. The Series A Convertible Preferred Stock is convertible at any time, at the Reporting Person's election, has no expiration date, and will automatically convert to shares of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-1 basis. The shares of Series A Convertible Preferred Stock are held by Lyell Investors, LLC. The Reporting Person is a manager of Lyell Investors, LLC (Lyell Investors) and may be deemed to share the power to direct the disposition and vote of the shares held by Lyell Investors. The Reporting Person disclaims beneficial ownership of all shares held by Lyell Investors except to any pecuniary interest therein. /s/ Heather D. Turner, as Attorney-in-fact 2021-06-16